BioSpace News Archive

ApiFix’s FDA and CE Mark approved less invasive non-fusion surgical system for treating progressive adolescent idiopathic scoliosis to enter broad distribution [02-April-2020] MISGAV, Israel , April 2, 2020 /PRNewswire/ -- The Trendlines Group Ltd. (“Trendlines” or the “Company”) is pleased to announce the 100% acquisition of portfolio company ApiFix Ltd. (“ApiFix”),

Orig3n and Codex Beauty announced a partnership that will enable consumers to better understand how genetics affect their skin, and maximize ingredients that support their health.

Eyenuk, Inc., a global artificial intelligence medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced that it completed the first quarter of 2020 with encouraging business results.

Seattle Genetics, Inc. (Nasdaq:SGEN) today provided an update on the phase 1b/2 multicohort EV-103 trial (also known as KEYNOTE-869) of PADCEV TM (enfortumab vedotin-ejfv) in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. Based on recent dis

Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5 th Candidate - Linear DNA Production for All Candidates Scheduled to Be Completed and Preclinical Animal Testing Expected to Commence This Month -

Aesthetic Medical International Holdings Group Limited announced the Company, through its affiliates, entered into definitive agreements to acquire controlling interest in two treatment centers in March 2020.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that the protocol for a planned physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea has been finalized.

China XD Plastics Company Limited, one of China’s leading specialty chemical companies engaged in the development, manufacture and sale of polymer composite materials primarily for automotive applications, provided an update on the impact of the coronavirus outbreak on its business and operations.

DexCom, Inc. announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, April 28, 2020.

Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.